Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Wegovy“
Suchtreffer
Begriffe & Kennungen
Wegovy · 4.8 · Patients with moderate renal impairment (eGFR ≥ 30 to < 60 mL/min/1.73 m2) may experience more gastrointestina
Eintrag öffnenWegovy · 4.8 · Patients with moderate renal impairment (eGFR ≥30 to < 60 mL/min/1.73m2) may experience more gastrointestinal
Eintrag öffnenWegovy · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenWegovy · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenWegovy · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenWegovy · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenWegovy · 4.8 · Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2
Eintrag öffnenWegovy · 4.8 · Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2
Eintrag öffnenWegovy · 4.8 · Summary of safety profile
Eintrag öffnenWegovy · 4.8 · Summary of safety profile
Eintrag öffnenWegovy · 4.8 · Table 1 Adverse reactions MedDRA Very Uncommo Very system Common Rare Not known common n rare organ class Immu
Eintrag öffnenWegovy · 4.8 · Table 1 lists adverse reactions identified in clinical trials in adults and post-marketing reports. The freque
Eintrag öffnenWegovy · 4.8 · Table 3 Adverse reactions MedDRA Very Uncommo system Common Rare Very Not known common n organ class rare Immu
Eintrag öffnenWegovy · 4.8 · Table 3 lists adverse reactions identified in clinical trials in adults and post-marketing reports. The freque
Eintrag öffnenWegovy · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenWegovy · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenWegovy · 4.8 · The below adverse reactions are applicable for oral semaglutide. Frequencies on specific adverse reactions, un
Eintrag öffnenWegovy · 4.8 · The below frequencies on specific adverse reactions, unless otherwise specified, pertains to the phase 3a tria
Eintrag öffnenWegovy · 4.8 · The gastrointestinal events led to permanent treatment discontinuation in 3.4% of patients treated with oral s
Eintrag öffnenWegovy · 4.8 · The gastrointestinal events led to permanent treatment discontinuation in 4.3% of patients.
Eintrag öffnen